Author(s)

David S. Younger, Beverley F. Murphy

Department of Clinical Medicine, CUNY School of Medicine, City College, New York, USA.

Despite leadership by dedicated lay organization and patient-based advocacy groups, the way forward for prospective candidates for disulfiram treatment has been difficult. This article provides the background, overview of disulfiram, in particular its intended use in post-treatment Lyme disease syndrome after a standard of care course of antibiotics fails to alleviate symptoms of tick borne disease. A series of recommendations are offered to guide patients and clinicians.

Disulfiram, Antabuse, Lyme Disease, Immune Globulin Therapy

Younger, D. and Murphy, B. (2020) Antabuse for Lyme Disease: The Way Forward. World Journal of Neuroscience, 10, 1-7. doi: 10.4236/wjns.2020.101001.